• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Armed with Phase III win, Incyte eyes label expansion for Monjuvi

cafead

Administrator
Staff member
  • cafead   Aug 16, 2024 at 11:42: AM
via Incyte has announced positive topline data from the Phase III inMIND trial evaluating its CD19-targeting monoclonal antibody Monjuvi (tafasitamab) in patients with relapsed or refractory (r/r) follicular lymphoma.

article source